EGFR and non-small cell lung carcinoma: Two third-generation EGFR-TKIs, aumolertinib and furmonertinib, were developed in China and subsequently approved by the NMPA on March 18, 2020 and March 3, 2021 for the treatment of advanced primary EGFR T790M-positive NSCLC and to supplement first- and second-generation EGFR-TKIs.37